Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$26.91 USD
-0.26 (-0.96%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $26.91 0.00 (0.00%) 7:32 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 101 - 120 ( 195 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
KOL Highlights Ensifentrine?s Differentiated Profile; Inflection Points in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ATS Abstracts Highlight Ensifentrine''s Safety/Efficacy Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q1: ATS, Steady Progress & Sufficient Cash to Pivotal COPD Readouts in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
pMDI Ensifentrine/COVID-19 Study Results; Next, Focus on COPD Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY20: Ensifentrine P3 Readouts On-Track for 2022; COVID Study data in Q2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
pMDI Ensifentrine/COPD: Positive Multiple Dose Phase 2 Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
PMDI Ensifentrine/COVID-19 Study Fully Enrolled; Topline Results in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
New Year''s Execution: Management Highlights From Analyst Call on the Year Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
$30M Debt Facility Provides Additional Financial Flexibility
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q3; COPD Ph3 Enrollment On-Track; Several Value-Creating Milestones in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Nebulized Ensifentrine/COPD Advances to Phase 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
pMDI Ensifentrine Enters into Phase 2 COVID-19 Pilot Study
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q2; On-Track to Begin COPD Ph 3 in H2; Multiple Dose pMDI Data in H1:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L